Useful information

CTX310: What the First Human Results Mean for Cholesterol

CTX310 is an investigational intravenous CRISPR therapy. In a 15-participant phase 1 study, the four-person 0.8 mg/kg cohort had mean day-60 reductions of 48.9% in LDL cholesterol and 55.2% in triglycerides; it is not an approved treatment.

Urinary tract infections in diabetic patients: why are they more frequent?

The Impact of Uncontrolled Glycemia on Sexual Life

Intracavernous injections: when are they indicated and how effective are they?

Hyaluronic acid injections for penile augmentation – indications and risks

Facial rejuvenation without surgery – natural lifting with HIFU, RF and laser

Shock wave therapy in erectile dysfunction – myth or real solution?

Treatment of erectile dysfunction: from pills to modern interventions

The role of diabetic neuropathy in the development of erectile dysfunction